Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 in Japanese Patients with CRPC and Bone Metastases
NCT01929655Phase 2Completed
- Sponsor
- Bayer
- Start
- Sep 2013
- Primary completion
- May 2017
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
A Phase 2 trial of radium-223 dichloride in castration-resistant prostate cancer (CRPC), bone metastases, sponsored by Bayer. Started Sep 2013; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
castration-resistant prostate cancer (CRPC)bone metastases
Beyond the preview
Go deeper on NCT01929655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01929655.